• 1
    Birchmeier C,Birchmeier W,Gherardi E,Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4: 91525.
  • 2
    Borowiak M,Garratt AN,Wustefeld T,Strehle M,Trautwein C,Birchmeier C. Met provides essential signals for liver regeneration. Proc Natl Acad Sci USA 2004; 101: 1060813.
  • 3
    Jiang WG,Martin TA,Parr C,Davies G,Matsumoto K,Nakamura T. Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit Rev Oncol Hematol 2005; 53: 3569.
  • 4
    Park M,Dean M,Cooper CS,Schmidt M,O'Brien SJ,Blair DG,Vande Woude GF. Mechanism of met oncogene activation. Cell 1986; 45: 895904.
  • 5
    Bottaro DP,Rubin JS,Faletto DL,Chan AM,Kmiecik TE,Vande Woude GF,Aaronson SA. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991; 251: 8024.
  • 6
    Zhang SZ,Pan FY,Xu JF,Yuan J,Guo SY,Dai G,Xue B,Shen WG,Wen CJ,Zhao DH,Li CJ. Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo. Mol Cancer Ther 2005; 4: 157784.
  • 7
    Shiota G,Rhoads DB,Wang TC,Nakamura T,Schmidt EV. Hepatocyte growth factor inhibits growth of hepatocellular carcinoma cells. Proc Natl Acad Sci USA 1992; 89: 3737.
  • 8
    Paumelle R,Tulasne D,Kherrouche Z,Plaza S,Leroy C,Reveneau S,Vandenbunder B,Fafeur V. Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway. Oncogene 2002; 21: 230919.
  • 9
    Santoni-Rugiu E,Preisegger KH,Kiss A,Audolfsson T,Shiota G,Schmidt EV,Thorgeirsson SS. Inhibition of neoplastic development in the liver by hepatocyte growth factor in a transgenic mouse model. Proc Natl Acad Sci USA 1996; 93: 957782.
  • 10
    Aydinlik H,Nguyen TD,Moennikes O,Buchmann A,Schwarz M. Selective pressure during tumor promotion by phenobarbital leads to clonal outgrowth of beta-catenin-mutated mouse liver tumors. Oncogene 2001; 20: 78126.
  • 11
    Monga SP,Mars WM,Pediaditakis P,Bell A,Mule K,Bowen WC,Wang X,Zarnegar R,Michalopoulos GK. Hepatocyte growth factor induces Wnt-independent nuclear translocation of beta-catenin after Met-beta-catenin dissociation in hepatocytes. Cancer Res 2002; 62: 206471.
  • 12
    Thompson MD,Monga SP. WNT/beta-catenin signaling in liver health and disease. Hepatology 2007; 45: 1298305.
  • 13
    Takami T,Kaposi-Novak P,Uchida K,Gomez-Quiroz LE,Conner EA,Factor VM,Thorgeirsson SS. Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis. Cancer Res 2007; 67: 984451.
  • 14
    Loeppen S,Koehle C,Buchmann A,Schwarz M. A beta-catenin-dependent pathway regulates expression of cytochrome P450 isoforms in mouse liver tumors. Carcinogenesis 2005; 26: 23948.
  • 15
    Wachstein M,Meisel E. Histochemistry of hepatic phosphatases of a physiologic pH; with special reference to the demonstration of bile canaliculi. Am J Clin Pathol 1957; 27: 1323.
  • 16
    Campbell HA,Pitot HC,Potter VR,Laishes BA. Application of quantitative stereology to the evaluation of enzyme-altered foci in rat liver. Cancer Res 1982; 42: 46572.
  • 17
    R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2004. ISBN 3-900051–003. Available at
  • 18
    Loeppen S,Schneider D,Gaunitz F,Gebhardt R,Kurek R,Buchmann A,Schwarz M. Overexpression of glutamine synthetase is associated with beta-catenin-mutations in mouse liver tumors during promotion of hepatocarcinogenesis by phenobarbital. Cancer Res 2002; 62: 56858.
  • 19
    Cadoret A,Ovejero C,Terris B,Souil E,Levy L,Lamers WH,Kitajewski J,Kahn A,Perret C. New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism. Oncogene 2002; 21: 8293301.
  • 20
    Strathmann J,Schwarz M,Tharappel JC,Glauert HP,Spear BT,Robertson LW,Appel KE,Buchmann A. PCB 153, a non-dioxin-like tumor promoter, selects for beta-catenin (Catnb)-mutated mouse liver tumors. Toxicol Sci 2006; 93: 3440.
  • 21
    Luebeck EG,Buchmann A,Schneider D,Moolgavkar SH,Schwarz M. Modulation of liver tumorigenesis in Connexin32-deficient mouse. Mutat Res 2005; 570: 3347.
  • 22
    Moolgavkar SH,Luebeck EG,de Gunst M,Port RE,Schwarz M. Quantitative analysis of enzyme-altered foci in rat hepatocarcinogenesis experiments–I. Single agent regimen. Carcinogenesis 1990; 11: 12718.
  • 23
    Buchmann A,Karcier Z,Schmid B,Strathmann J,Schwarz M. Differential selection for B-raf and Ha-ras mutated liver tumors in mice with high and low susceptibility to hepatocarcinogenesis. Mutat Res 2008; 638: 6674.
  • 24
    Jaworski M,Buchmann A,Bauer P,Riess O,Schwarz M. B-raf and Ha-ras mutations in chemically induced mouse liver tumors. Oncogene 2005; 24: 12905.
  • 25
    Yamamoto Y,Moore R,Goldsworthy TL,Negishi M,Maronpot RR. The orphan nuclear receptor constitutive active/androstane receptor is essential for liver tumor promotion by phenobarbital in mice. Cancer Res 2004; 64: 7197200.
  • 26
    Pustylnyak VO,Zakharova LY,Mikhailova ON,Rice RH,Gulyaeva LF,Lyakhovich VV. In vivo effects of protein kinase and phosphatase inhibitors on CYP2B induction in rat liver. Toxicology 2005; 207: 31522.
  • 27
    Swales K,Negishi M. CAR, driving into the future. Mol Endocrinol 2004; 18: 158998.
  • 28
    Yu LG,Packman LC,Weldon M,Hamlett J,Rhodes JM. Protein phosphatase 2A, a negative regulator of the ERK signaling pathway, is activated by tyrosine phosphorylation of putative HLA class II-associated protein I (PHAPI)/pp32 in response to the antiproliferative lectin, jacalin. J Biol Chem 2004; 279: 4137783.
  • 29
    Kakizaki S,Yamazaki Y,Kosone T,Horiguchi N,Sohara N,Sato K,Takagi H,Yoshinari K,Mori M. Gene expression profiles of drug-metabolizing enzymes and transporters with an overexpression of hepatocyte growth factor. Liver Int 2007; 27: 10919.
  • 30
    Koike C,Moore R,Negishi M. Extracellular signal-regulated kinase is an endogenous signal retaining the nuclear constitutive active/ androstane receptor (CAR) in the cytoplasm of mouse primary hepatocytes. Mol Pharmacol 2007; 71: 121721.